Improvement of HIV-specific immunity in HIV-infected twins treated with highly active antiretroviral therapy, interleukin 2, and syngeneic adoptively transferred cells

AIDS Research and Human Retroviruses

Volumn 17, Issue 10, 2001, Pages 887-900

  Tsoukas, Christos M ^a,g   Turner, Howard M ^a   Hatzakis, George E ^a   Blake, Goeffrey P ^b   Goodhew, John E ^c   Kilby, Donald L P ^d   Kovacs, Colin M ^e   Luetkehoelter, Jonathan R ^c   Routy, Jean Pierre ^b   Walmsley, Sharon L ^f   Bernard, Nicole F ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Toronto HIV Primary Care Physicians' Group   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g Immunodeficiency Treatment Center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GAMMA INTERFERON; INDINAVIR; INTERLEUKIN 2; LAMIVUDINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOPTIVE IMMUNOTHERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; LYMPHOCYTOTOXICITY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; TWINS; VACCINIA; VIRUS IMMUNITY; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DISEASES IN TWINS; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; IMMUNOASSAY; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PILOT PROJECTS; TWINS, MONOZYGOTIC; VIRAL LOAD;

EID: 0034821256     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922201750290014     Document Type: Article

References (59)

1. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
2. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men: HIV affects the immune system before CD4+ T cell depletion occurs
3. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic human immunodeficiency virus-seropositive patients
4. Human immunodeficiency virus infection in the US Air Force: Seroconversions, clinical staging and assessment of T helper cell functional assay to predict change in CD4+ T cell counts
5. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection prior antiretroviral therapy
6. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
7. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
8. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir
9. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral thearpy
10. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1
11. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults
12. HAART in HIV-infected patients: Restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia
13. Recovery of the immune system with antiretroviral therapy: The end of opportunism?
14. Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis
15. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection
16. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
17. HIV infection induces changes in CD4+ T-cell phenotype and depletions with the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
18. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons
19. Protection against syngeneic lymphoma by a long-lived cytotoxic T cell clone
20. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMuLV-specific T cell clones
21. Retrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo
22. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes
23. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
24. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
25. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression
26. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients
27. In vivo migration function of transferred HIV-1-specific cytotoxic T cells
28. Prolonged CD8+ T-cell expansions after adoptive transfer of syngeneic lymphocytes between HIV-discordant identical twins
29. Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults
30. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome
31. A phase I study of adoptive transfer of autologous CD8+ T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS
32. Generation and characterization of ex vivo propagated autologous CD8+ cells used for adoptive immunotherapy of patients infected with human immunodeficiency virus
33. Clinical and immunological changes in AIDS patients following adoptive therapy with activated autologous CD8 T cells and interleukin-2 infusion
34. Human immunodeficiency virus (HIV) specific cytotoxic T lymphocyte activity in immunologically normal HIV-infected persons
35. Effects of human immunodeficiency virus on the cellular immune response to Epstein-Barr virus in homosexual men: Characterization of the cytotoxic response and lymphokine production
36. Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection
37. Partial immune reconstitution in a patient with the acquired immunodeficiency syndrome
38. A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins
39. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy
40. 3despite effective HAART
41. 3: Results of a randomised controlled trial MA-9801
42. Viral immune evasion due to persistence of activated T cells without effector function
43. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection
44. Enhanced establishment of a virus state in adult CD4-T cell deficient mice
45. Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells
46. Critical role for CD4(+) T cells in controlling retrovirus replication and spread in persistently infected mice
47. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients
48. IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection
49. Downregulation of Bcl-2, but not of Bax or Bcl-x, is associated with T lymphocyte apoptosis in HIV infection and restored by antiretroviral therapy or by interleukin 2
50. Apoptosis in HIV infection: Protective role of IL-2
51. Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: Correlation with disease progression
52. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector memory responses decline after suppression of viremia with highly active antiretroviral therapy
53. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
54. Molecular tracking of an human immunodeficiency virus Nef specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy
55. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load
56. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy
57. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
58. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation